查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1698493

次世代定序儀市場：2025-2030 年預測

Next Generation Sequencers Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計次世代定序儀(NGS) 市場在預測期內（即 2025-2030 年）的複合年成長率為 7.35%。

次世代定序儀是一種大規模平行定序技術，具有可擴展性、超高通量和速度。它可用於確定完整基因組中核苷酸的順序。 DNA定序是整個定序方法中最重要的步驟之一，涉及為後續定序反應準備材料。在全球範圍內，NGS正逐漸被納入臨床實驗室分析、檢測和疾病診斷。藥物基因組學已做出了巨大努力來加快藥物發現過程。基因組圖譜計劃、次世代定序儀應用、醫療保健支出和技術改進是預測期內推動次世代定序儀市場成長的主要因素。

市場趨勢：

  • 次世代定序儀市場的成長：由於能夠透過鹼基定序對整個基因組進行定序，次世代定序儀市場正在不斷擴大。過程中的關鍵步驟是 DNA 預測序，它為後續的定序反應準備樣本，是任何定序通訊協定的基石。在全球範圍內，NGS 擴大融入醫學實驗室分析、疾病評估和診斷。在藥物基因組學中，NGS 被廣泛用於加速藥物發現。行業參與者旨在提高診斷能力的重大創新和發展預計將成為未來幾年市場發展的主要驅動力。例如，2023 年 3 月，SOPHiA GENETICS 與 Qiagen 合作，利用 NGS 推進腫瘤分析。此次合作將 QIAseq 試劑技術與 SOPHiA DDM 平台相結合，使客戶能夠透過 SOPHiA DDM™ 存取處理過的 QIAseq 面板 - SOPHiA DDM™ 是一種雲端基礎的工具，可分析來自各種來源的數據以解鎖新的研究見解。最初，夥伴關係將專注於同源重組修復 (HRR)，這是一種生物標記測試，用於識別可能對腫瘤學中的 PARP 抑制劑有反應的突變腫瘤，利用 QIAseq Targeted DNA Pro Panel 進行體細胞突變檢測。
  • 區域市場洞察：全球次世代定序儀市場分為北美、南美、歐洲、中東和非洲以及亞太地區。北美已成為全球領先的 NGS 市場，預計未來幾年仍將保持這一主導地位。 NGS 技術在常規臨床診斷中的日益普及是一個主要促進因素。該地區的市場擴張受到慢性病和感染疾病病率上升、基因組學投資增加以及主要行業參與者取得重大進展等因素的進一步支持。例如，加拿大癌症協會估計，2024 年將有 6,600 名加拿大人被診斷出罹患白血病。同時，美國衛生與公共服務部報告同年新增 62,770 例病例，佔所有新癌症診斷的 3.1%。日益加重的疾病負擔刺激了對創新檢測和診斷解決方案的需求，推動了整個預測期內的市場成長。

本報告涉及的主要企業包括 Quest Diagnostics Incorporated、ARUP Laboratories、Applied Biological Materials, Inc. (ABM)、Novogene Co. Ltd.、Azenta Life Sciences (GENEWIZ) 和 NanoString。

本報告的主要優點

  • 深刻分析：獲得涵蓋主要和新興地區的深入市場洞察，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、垂直行業和其他子區隔。
  • 競爭格局：了解全球主要企業所採用的策略策略，並了解正確策略帶來的潛在市場滲透。
  • 市場趨勢和促進因素：探索動態因素和關鍵市場趨勢以及它們將如何影響未來的市場發展。
  • 可行的建議：利用洞察力進行策略決策，在動態環境中開闢新的業務流和收益。
  • 適用範圍廣：對於新興企業、研究機構、顧問公司、中小企業和大型企業來說，它都是實用且具有成本效益的。

它有什麼用途？

產業和市場考量、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本支出決策、法律規範與影響、新產品開發、競爭影響

研究範圍

  • 2022 年至 2024 年的歷史數據和 2025 年至 2030 年的預測數據
  • 成長機會、挑戰、供應鏈前景、法規結構、趨勢分析
  • 競爭市場條件、策略與市場佔有率分析
  • 對各細分市場和地區（包括國家）的收益成長和預測評估
  • 公司簡介（策略、產品、財務資訊、主要發展等）

目錄

第1章 引言

  • 市場概覽
  • 市場定義
  • 研究範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要利益

第2章調查方法

  • 研究設計
  • 研究過程

第3章執行摘要

  • 主要發現
  • 分析師觀點

第4章 市場動態

  • 市場促進因素
  • 市場限制
  • 波特五力分析
  • 產業價值鏈分析

第5章次世代定序儀市場（按產品）

  • 介紹
  • 產品
  • 服務

第6章次世代定序儀市場（依技術）

  • 介紹
  • 邊合成邊定序
  • 離子半導體定序
  • 單分子即時定序
  • 奈米孔定序
  • 其他

第7章次世代定序儀市場（依應用）

  • 介紹
  • 診斷
  • 藥物研發
  • 生物標記發現
  • 農業和動物研究
  • 其他

第8章次世代定序儀市場（依最終用戶）

  • 介紹
  • 醫院和診所
  • 製藥和生物技術公司
  • 學術和研究機構
  • 其他

第9章次世代定序儀市場（按地區）

  • 世界概況
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 其他
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 印尼
    • 泰國
    • 其他

第10章競爭格局及分析

  • 主要企業和策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭儀錶板

第11章 公司簡介

  • Quest Diagnostics Incorporated
  • ARUP Laboratories
  • Applied Biological Materials, Inc.（ABM）
  • Novogene Co., Ltd.
  • Azenta Life Sciences（GENEWIZ）
  • NanoString
  • Illumina, Inc.
  • PacBio
  • Qiagen
  • Thermo Fisher Scientific
簡介目錄
Product Code: KSI061615484

The next-generation sequencers market is expected to grow at a CAGR of 7.35% during the projected period from 2025 to 2030.

Next-generation sequencing (NGS) is a massively parallel sequencing technology that enables scalability, ultra-high throughput, and quick speed. It can be used to establish the order of the nucleotides in the complete genome. DNA pre-sequencing is one of the most crucial steps in the entire sequencing methodology, which involves preparing the material for the following sequencing reaction. Globally, NGS is being gradually included in clinical laboratory analysis, testing, and illness diagnosis. Pharmacogenomics has made extensive efforts to speed up the drug discovery process. Genome mapping programs, next-generation sequencing applications, healthcare spending, and technology improvements are the main factors driving the next-generation sequencers market growth during the projected period.

Market Trends:

  • Growth of the Next-Generation Sequencing Market: The next-generation sequencing (NGS) market is expanding due to its ability to sequence entire genomes by determining nucleotide sequences. A critical step in this process is DNA pre-sequencing, which prepares samples for subsequent sequencing reactions, making it a cornerstone of the sequencing protocol. Worldwide, NGS is increasingly integrated into medical laboratory analysis, disease evaluation, and diagnostics. In pharmacogenomics, NGS is widely utilized to accelerate drug discovery. Key innovations and developments by industry players aimed at enhancing diagnostic capabilities are expected to drive significant market growth in the coming years. For example, in March 2023, SOPHiA GENETICS partnered with Qiagen to advance tumor analysis through NGS. This collaboration combined QIAseq reagent technology with the SOPHiA DDM platform, enabling customers to access QIAseq panels processed via SOPHiA DDM(TM)-a cloud-based tool that analyzes data from various sources to unlock new research insights. Initially, the partnership focuses on homologous recombination repair (HRR), a biomarker test identifying tumors with mutations that may respond to PARP inhibitors in oncology, utilizing QIAseq Targeted DNA Pro panels for somatic variant detection.
  • Regional Market Insights: The global next-generation sequencers market is segmented into North America, South America, Europe, the Middle East and Africa, and Asia Pacific. North America is projected to emerge as a leading market for NGS worldwide and is expected to maintain this dominance for several years. The growing adoption of NGS technology in routine clinical diagnostics is a key driver. Market expansion in this region is further supported by factors such as the increasing incidence of chronic and infectious diseases, rising investments in genomics, and significant advancements by major industry players. For instance, the Canadian Cancer Society estimates that 6,600 Canadians will be diagnosed with leukemia in 2024, while the US Department of Health and Human Services reported 62,770 new cases in the same year, representing 3.1% of all new cancer diagnoses. This rising disease burden is fueling demand for innovative detection and diagnostic solutions, propelling market growth throughout the forecast period.

Some of the major players covered in this report include Quest Diagnostics Incorporated, ARUP Laboratories, Applied Biological Materials, Inc. (ABM), Novogene Co., Ltd., Azenta Life Sciences (GENEWIZ), NanoString, among others.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2022 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

The Next Generation Sequencers Market is segmented and analyzed as follows:

By Offering

  • Product
  • Services

By Technology

  • Sequencing By Synthesis
  • Ion Semiconductor Sequencing
  • Single-molecule Real-time Sequencing
  • Nanopore Sequencing
  • Others

By Application

  • Diagnostics
  • Drug Discovery
  • Biomarker Discovery
  • Agriculture & Animal Research
  • Others

By End-User

  • Hospitals & Clinics
  • Pharmaceutical & Biotechnology Companies
  • Academics & Research Institutes
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key benefits for the stakeholders

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Process

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. Analyst View

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. The Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. NEXT GENERATION SEQUENCERS MARKET BY OFFERING

  • 5.1. Introduction
  • 5.2. Product
  • 5.3. Services

6. NEXT GENERATION SEQUENCERS MARKET BY TECHNOLOGY

  • 6.1. Introduction
  • 6.2. Sequencing By Synthesis
  • 6.3. Ion Semiconductor Sequencing
  • 6.4. Single-molecule Real-time Sequencing
  • 6.5. Nanopore Sequencing
  • 6.6. Others

7. NEXT GENERATION SEQUENCERS MARKET BY APPLICATION

  • 7.1. Introduction
  • 7.2. Diagnostics
  • 7.3. Drug Discovery
  • 7.4. Biomarker Discovery
  • 7.5. Agriculture & Animal Research
  • 7.6. Others

8. NEXT GENERATION SEQUENCERS MARKET BY END-USER

  • 8.1. Introduction
  • 8.2. Hospitals & Clinics
  • 8.3. Pharmaceutical & Biotechnology Companies
  • 8.4. Academics & Research Institutes
  • 8.5. Others

9. NEXT GENERATION SEQUENCERS MARKET BY GEOGRAPHY

  • 9.1. Global Overview
  • 9.2. North America
    • 9.2.1. United States
    • 9.2.2. Canada
    • 9.2.3. Mexico
  • 9.3. South America
    • 9.3.1. Brazil
    • 9.3.2. Argentina
    • 9.3.3. Others
  • 9.4. Europe
    • 9.4.1. United Kingdom
    • 9.4.2. Germany
    • 9.4.3. France
    • 9.4.4. Spain
    • 9.4.5. Others
  • 9.5. Middle East and Africa
    • 9.5.1. Saudi Arabia
    • 9.5.2. UAE
    • 9.5.3. Israel
    • 9.5.4. Others
  • 9.6. Asia-Pacific
    • 9.6.1. Japan
    • 9.6.2. China
    • 9.6.3. India
    • 9.6.4. South Korea
    • 9.6.5. Indonesia
    • 9.6.6. Thailand
    • 9.6.7. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Competitive Dashboard

11. COMPANY PROFILES

  • 11.1. Quest Diagnostics Incorporated
  • 11.2. ARUP Laboratories
  • 11.3. Applied Biological Materials, Inc. (ABM)
  • 11.4. Novogene Co., Ltd.
  • 11.5. Azenta Life Sciences (GENEWIZ)
  • 11.6. NanoString
  • 11.7. Illumina, Inc.
  • 11.8. PacBio
  • 11.9. Qiagen
  • 11.10. Thermo Fisher Scientific